此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

早期访问计划指南,旨在与卡泊粉蛋白和紫杉醇一起提供乙状结证(INCMGA00012)的访问权限

2026年1月6日 更新者:Incyte Corporation

To provide retifanlimab, on a reactive basis, to adult patients with squamous carcinoma of the anal canal in combination with carboplatin and paclitaxel and who are considered ineligible for other therapeutic options including clinical trials.

研究概览

地位

可用的

研究类型

扩展访问

扩展访问类型

  • 个体患者

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不适用

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Able to comprehend and willing to sign a written ICF for the study.

  • Are 18 years of age or older (or as applicable per local country requirements).

  • Histologically or cytologically verified, inoperable locally recurrent or metastatic SCAC.

  • Adequate ECOG performance status to be able to benefit from the treatment.

  • If HIV-positive, a well controlled and stable disease and receiving antiretroviral therapy (ART/HAART) and have not experienced any HIV-related opportunistic infection for at least 4 weeks prior to study enrollment.

  • Willingness to avoid pregnancy or fathering children based on the criteria below.

    • Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through 120 days after the last dose of INCMGA00012 or placebo or through 180 days after the last dose of chemotherapeutic agents, whichever occurs later (or longer as appropriate based on country-specific requirements) and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed.
    • Women of childbearing potential must have a negative serum pregnancy test at screening, agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty), and refrain from donating oocytes from screening through 120 days after the last dose of INCMGA00012 or placebo or through 180 days after the last dose of chemotherapeutic agents, whichever occurs later. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed. The definition of WOCBP is located in the protocol.
    • Women of nonchildbearing potential are eligible as defined in the protocol.

Exclusion Criteria:

  • Has received prior PD-(L)1 directed therapy.
  • Participants must have recovered from previous therapies for example including but not limited to RT and CRT.
  • Participants with laboratory values at screening defined below:

Hematology:

  • Platelets < 100 × 109/L.
  • Hemoglobin < 9 g/dL.
  • ANC < 1.5 x 109/L.

Hepatic:

  • ALT ˃ 2.5 x ULN or ˃ 5 x ULN for participants with liver metastases.
  • AST ˃ 2.5 x ULN or ˃ 5 x ULN for participants with liver metastases.
  • Bilirubin ≥ 1.5 x ULN unless conjugated bilirubin ≤ ULN (conjugated bilirubin only needs to be tested if total bilirubin exceeds ULN). If there is no institutional ULN, then direct bilirubin must be < 40% of total bilirubin.

Renal:

• Calculated creatinine clearance < 50 mL/min calculated by Cockcroft-Gault equation (glomerular filtration rate can also be used in place of CrCl).

Coagulation:

  • INR or PT > 1.5 × ULN, for participants not receiving anticoagulant therapy.

  • aPTT > 1.5 × ULN for participants not receiving anticoagulant therapy.

    • Active autoimmune disease requiring systemic immunosuppression in excess of physiologic maintenance doses of corticosteroids (> 10 mg of prednisone or equivalent).
    • Evidence of interstitial lung disease or active noninfectious pneumonitis.
    • History of organ transplant, including allogeneic stem cell transplantation.
    • Known active CNS metastases and/or carcinomatous meningitis, per the protocol.
    • Known active HAV, HBV, or HCV infection, as defined by elevated transaminases with the following serology: positivity for HAV IgM antibody, anti-HCV, anti-HBc IgG or IgM, or HBsAg (in the absence of prior immunization).
    • Active infections requiring systemic therapy, or IV antibiotic use up to 7 days before Cycle 1 Day 1.
    • Known hypersensitivity to platinum, paclitaxel, another monoclonal antibody, or any of the excipients that cannot be controlled with standard measures (eg, antihistamines, corticosteroids).
    • Participants with impaired cardiac function or clinically significant cardiac disease as assessed by the treating physician.
    • Participant is pregnant or breastfeeding.
    • Has pre-existing peripheral neuropathy that is ≥ Grade 2 by CTCAE v5.
    • Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究注册日期

首次提交

2025年3月27日

首先提交符合 QC 标准的

2025年3月27日

首次发布 (实际的)

2025年4月4日

研究记录更新

最后更新发布 (实际的)

2026年1月8日

上次提交的符合 QC 标准的更新

2026年1月6日

最后验证

2026年1月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅